Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase III study of Efpeglenatide for obesity

Trial Profile

A phase III study of Efpeglenatide for obesity

Phase of Trial: Phase III

Latest Information Update: 18 Dec 2017

At a glance

  • Drugs Efpeglenatide (Primary)
  • Indications Obesity
  • Focus Therapeutic Use
  • Most Recent Events

    • 18 Dec 2017 New trial record
    • 13 Dec 2017 According to a Sanofi media release, the company expects to initiate this study in 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top